FTSV Forty Seven Inc.

10.12
-0.16  -2%
Previous Close 10.28
Open 10.23
Price To Book 2.81
Market Cap 317,351,542
Shares 31,358,848
Volume 141,154
Short Ratio
Av. Daily Volume 226,734

NewsSee all news

  1. Forty Seven Wins Exclusive License Deal For 5F9
  2. Have Insiders Been Buying Forty Seven, Inc. (NASDAQ:FTSV) Shares?
  3. Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
  4. Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
  5. Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data at EHA noted ORR 36% in DLBCL and ORR 61% in Indolent Lymphoma.
5F9 + rituximab
Non-Hodgkin Lymphoma (NHL) - cancer
Phase 1b/2 data due 4Q 2019.
5F9 + cetuximab
Colorectal cancer
Phase 1b data at ASCO June 3, 2019 noted 10% ORR.
5F9
Acute myeloid leukemia (AML)
Phase 1b data noted 64% ORR (untreated AML) and 100% for higher risk MDS patients.
5F9 + Azacitidine
Acute myeloid leukemia (AML)
Phase 1 trial ongoing.
5F9
Solid tumors
Phase 1b data due 4Q 2019.
5F9 + Avelumab
Ovarian cancer

Latest News

  1. Forty Seven Wins Exclusive License Deal For 5F9
  2. Have Insiders Been Buying Forty Seven, Inc. (NASDAQ:FTSV) Shares?
  3. Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
  4. Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
  5. Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
  6. Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association
  7. Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting
  8. Forty Seven Inc. (FTSV) Q1 2019 Earnings Call Transcript
  9. Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights
  10. Forty Seven, Inc. to Host Earnings Call
  11. Were Hedge Funds Right About Dumping Forty Seven, Inc. (FTSV)?
  12. Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019
  13. Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s Lymphoma
  14. Top Ranked Momentum Stocks to Buy for April 25th
  15. Could Forty Seven, Inc.'s (NASDAQ:FTSV) Investor Composition Influence The Stock Price?
  16. Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
  17. Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 28, 2019
  18. Forty Seven Inc. to Present at Oppenheimer 29th Annual Healthcare Conference
  19. Health Care Digest: Salesforce's DNA leads deeper into health, a defiant cancer startup and more